Viewing Study NCT03518320


Ignite Creation Date: 2025-12-25 @ 4:18 AM
Ignite Modification Date: 2026-03-06 @ 6:14 PM
Study NCT ID: NCT03518320
Status: TERMINATED
Last Update Posted: 2024-08-27
First Post: 2018-04-10
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Sponsor: Taris Biomedical LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module